Trial Profile

A phase 3 pivotal trial of EO2463

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 17 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EO 2463 (Primary)
Indications Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
Focus Registrational; Therapeutic Use

Most Recent Events

17 Jun 2025 New trial record
12 Jun 2025 According to Enterome Media Release, company raises $19 million to fund Phase 1/2 SIDNEY clinical trial of EO2463 and prepare to launch a first pivotal Phase 3 trial of this candidate for the watch-and-wait iNHL population.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com